State Activities: Impact on the U.S. Pharmaceutical IndustryDecision Resources
June 25, 2007
35 Pages - SKU: DECR1507364
Additional InformationKey Players Mentioned in This Spectrum Report:
Association (AMA) AstraZeneca
Attorney General Kelly A.
Ayotte, New Hampshire Center for Public Policy
Centers for Medicare and
Medicaid Services (CMS) Congressional Budget
Offi ce (CBO) Eli Lilly
First Circuit Court of
Appeals, Boston GlaxoSmithKline
Governor John Lynch,
New Hampshire Homeland Security
Appropriations Bill of 2007 Judge Paul Barbadoro,
New Hampshire Medicine Equity and Drug
Safety Act of 2000 (MEDS Act) Medicare Part D
Drug Act (MMA) National Conference on
State Legislatures (NCSL) National Do Not Call
Registry NH’s Prescription
Information Law Pfi zer
Access and Drug Safety Act Pharmacy benefi t managers
(PBMs) Prescribing Data
Restriction Program (PDRP) Rep. Rahm Emanuel
(D-IL) Safe Importation of
Medical Products and Other Rx Therapies Act of 2004 Secretary of Health and
Human Services (HHS) Sen. Barack Obama (D-IL)
Sen. Byron Dorgan
(D-ND) Sen. Hillary Rodham
Clinton (D-NY) Sen. John McCain (R-AZ)
Sen. Olympia Snowe
(R-ME) State attorneys general
The Senior Citizens
League (TSCL) U.S. Customs and Border
Protection U.S. District Court, District
of New Hampshire U.S. House of
Representatives U.S. Senate
More Prescription Drugs reports by Decision Resources
Turkey: Market Access Tracker by Decision Resources
The Turkish pharmaceutical market is the 6th largest in Europe and the 16th largest in the world and experienced rapid growth until 2011. A ...
Italy: Market Access Tracker by Decision Resources
The Italian pharmaceutical market is the third largest in Europe and the eighth largest in the world, with ex-manufacturer sales in retail pharmacies ...
Market Access Obstacles in the European Gout Market: Physician and Payer Perspectives on Opportunities for Novel Acute and Chronic Gout Therapies by Decision Resources
The European gout market is mature and highly genericized. First-line treatment for gout is dominated by the xanthine oxidase inhibitor allopurinol, which has ...
LaunchTrends®: Enzalutimide (Xtandi) (Wave 1) US 2012 by Decision ResourcesSee all reports like this >>
LaunchTrends®: Xtandi (enzalutamide, formerly known as MDV-3100) is a three wave primary research study will follow the launch of Xtandi for the treatment of prostate ...
More United States Prescription Drugs reports
United States Pharmaceuticals and Healthcare Report Q2 2013 by Business Monitor International
BMI View: For years to come, the US pharmaceutical market will remain the most attractive todrugmakers. Considerable absolute sales figures and high expected growth are ...
Brand Name Pharmaceutical Manufacturing in the US - Industry Risk Rating Report by IBISWorld
Industry Risk Ratings SynopsisThis Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Brand Name Pharmaceutical Manufacturing in the US industry. ...
Cough, Cold and Allergy (Hay Fever) Remedies in the US by Euromonitor International
Executive Summary TRENDS Cough, cold and allergy (hay fever) remedies faced several challenges in 2012. First, the 2011-2012 flu season was unusually mild. Warmer ...
The U.S. Market for Urgent Care Centers by Kalorama InformationSee all reports like this >>
Urgent care centers in the United States provide an increasingly important option between a physician’s office and a hospital emergency room. They provide ...
More United States reports
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
We can help you find what you need. Call us or write us:
Need help in your search?
Prescription Drugs Reports